CTNM

Contineum Therapeutics, Inc.
CAPPED RATING

Contineum Therapeutics, Inc. (CTNM) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F). The rating has held at D+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.5 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.1
EV / EBITDA -2.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -29.5%
Price Return 12M -3.3%
Catalyst Signal 0.00
Market Cap $414.6M
TTM Revenue N/A
Price / Sales N/A
ROE -29.8%

Historical Factor Score Progression

Held D+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D+ (1.5) C (2.2) D+ (1.7) F (0.0) D+ (1.6)
2026-11-04 C+ (2.5) D+ (1.6) C (2.2) C (2.2) F (0.0) D+ (1.7)
2026-10-28 C+ (2.5) D+ (1.5) C (2.4) C (2.2) F (0.0) D+ (1.7)
2026-10-21 C+ (2.5) D+ (1.5) C (2.4) C (2.2) F (0.0) D+ (1.7)
2026-10-14 C+ (2.5) D+ (1.5) C (2.4) C (2.4) C+ (2.6) C (2.3)
Page 1 of 4